Michael E. Stokes

3.2k total citations · 1 hit paper
50 papers, 2.2k citations indexed

About

Michael E. Stokes is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Michael E. Stokes has authored 50 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pulmonary and Respiratory Medicine, 16 papers in Oncology and 10 papers in Molecular Biology. Recurrent topics in Michael E. Stokes's work include Ferroptosis and cancer prognosis (5 papers), Economic and Financial Impacts of Cancer (5 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Michael E. Stokes is often cited by papers focused on Ferroptosis and cancer prognosis (5 papers), Economic and Financial Impacts of Cancer (5 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Michael E. Stokes collaborates with scholars based in United States, United Kingdom and Japan. Michael E. Stokes's co-authors include Brent R. Stockwell, J. Csuka, Hannah Bender, Kôji Uchida, Benjamin G. Hoffstrom, Peter Canoll, Presha Rajbhandari, Rajesh K. Soni, Aubrianna Decker and Pavan S. Upadhyayula and has published in prestigious journals such as Cell, Journal of Clinical Oncology and Genes & Development.

In The Last Decade

Michael E. Stokes

45 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Transferrin Receptor Is a Specific Ferroptosis Marker

2020 640 citations Michael E. Stokes et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Michael E. Stokes United States	19	881	824	580	395	210	50	2.2k
Channing J. Paller United States	31	2.2k 2.5×	963 1.2×	930 1.6×	924 2.3×	152 0.7×	145	3.8k
Victoria M. Pratt United States	33	397 0.5×	952 1.2×	288 0.5×	381 1.0×	156 0.7×	106	3.3k
Teresa A. Smolarek United States	26	528 0.6×	742 0.9×	173 0.3×	599 1.5×	295 1.4×	68	2.2k
Kathrin Strasser‐Weippl Austria	20	408 0.5×	657 0.8×	864 1.5×	1.2k 3.1×	100 0.5×	61	2.5k
Tom Boterberg Belgium	36	1.3k 1.4×	762 0.9×	422 0.7×	1.2k 3.0×	1.1k 5.5×	167	4.2k
Andrew Stone United Kingdom	23	407 0.5×	1.1k 1.3×	542 0.9×	753 1.9×	112 0.5×	59	2.9k
Mansoor M. Ahmed United States	35	1.1k 1.3×	1.1k 1.3×	454 0.8×	985 2.5×	318 1.5×	116	3.5k
Ying Zheng China	29	412 0.5×	987 1.2×	608 1.0×	755 1.9×	177 0.8×	104	2.8k
Gabriella D’Andrea United States	24	848 1.0×	785 1.0×	383 0.7×	1.5k 3.8×	68 0.3×	60	2.7k
Elizabeth Thompson United States	22	460 0.5×	573 0.7×	234 0.4×	237 0.6×	427 2.0×	58	2.5k

Countries citing papers authored by Michael E. Stokes

Since Specialization

Citations

This map shows the geographic impact of Michael E. Stokes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael E. Stokes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael E. Stokes more than expected).

Fields of papers citing papers by Michael E. Stokes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael E. Stokes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael E. Stokes. The network helps show where Michael E. Stokes may publish in the future.

Co-authorship network of co-authors of Michael E. Stokes

This figure shows the co-authorship network connecting the top 25 collaborators of Michael E. Stokes. A scholar is included among the top collaborators of Michael E. Stokes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael E. Stokes. Michael E. Stokes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dudek, Arkadiusz Z., Joyce O’Shaughnessy, Sarina A. Piha‐Paul, et al.. (2024). A multicenter, open-label, phase 1a study of HC-5404 in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). e15118–e15118. 10 indexed citations

Stokes, Michael E., Verónica Calvo, Sho Fujisawa, et al.. (2023). PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors. Clinical Cancer Research. 29(23). 4870–4882. 16 indexed citations

Calvo, Verónica, Wei Zheng, Anna Adam‐Artigues, et al.. (2023). A PERK-Specific Inhibitor Blocks Metastatic Progression by Limiting Integrated Stress Response–Dependent Survival of Quiescent Cancer Cells. Clinical Cancer Research. 29(24). 5155–5172. 23 indexed citations

Tolaney, Sara M., Kevin Punie, Allison W. Kurian, et al.. (2023). Real-world clinical outcomes in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US).. Journal of Clinical Oncology. 41(16_suppl). e18871–e18871. 1 indexed citations

Stokes, Michael E., M. D. Surman, Verónica Calvo, et al.. (2022). Optimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors. Pharmaceutics. 14(10). 2233–2233. 5 indexed citations

Li, Qian, et al.. (2022). Comparison of utilization and cost of healthcare services and pharmacotherapy following implantation of vagus nerve stimulation vs. responsive neurostimulation or deep brain stimulation for the treatment of drug-resistant epilepsy: analyses of a large United States healthcare claims database. Journal of Medical Economics. 25(1). 1218–1230. 5 indexed citations

Pai, Sara I., Ezra E.W. Cohen, Derrick Lin, et al.. (2019). SUPREME-HN: a retrospective biomarker study assessing the prognostic value of PD-L1 expression in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. Journal of Translational Medicine. 17(1). 429–429. 6 indexed citations

Pai, Sara I., Ezra E.W. Cohen, Derrick Lin, et al.. (2017). RetroSpective cohort stUdy of PD-L1 expression in REcurrent and/or MEtastatic squamous cell carcinoma of the head and neck (SUPREME-HN). Annals of Oncology. 28. v374–v375. 4 indexed citations

Stokes, Michael E., Sophie Wildsmith, Maria Secrier, et al.. (2017). Relationship between PD-L1 expression and survival in head and neck squamous cell carcinoma (HNSCC) patients (pts). Annals of Oncology. 28. v375–v375. 5 indexed citations

10.

Galaznik, Aaron, Jill A. Bell, Michael E. Stokes, et al.. (2016). Systematic Review of Therapy Used in Relapsed or Refractory Diffuse Large B-Cell Lymphoma. Blood. 128(22). 3562–3562. 1 indexed citations

11.

Toh, Shigeo, Duncan Holbrook‐Smith, Michael E. Stokes, Yuichiro Tsuchiya, & Peter McCourt. (2014). Detection of Parasitic Plant Suicide Germination Compounds Using a High-Throughput Arabidopsis HTL/KAI2 Strigolactone Perception System. Chemistry & Biology. 21(9). 1253–1253. 6 indexed citations

12.

Stokes, Michael E., Libby Black, Ágnes Benedict, Claus G. Roehrborn, & Peter C. Albertsen. (2010). Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data. Prostate Cancer and Prostatic Diseases. 13(3). 278–284. 26 indexed citations

13.

Fourcade, R., Ágnes Benedict, Libby Black, et al.. (2009). Treatment costs of prostate cancer in the first year after diagnosis: a short‐term cost of illness study for France, Germany, Italy, Spain and the UK. British Journal of Urology. 105(1). 49–56. 53 indexed citations

14.

Roehrborn, Claus G., Peter C. Albertsen, Michael E. Stokes, Libby Black, & Ágnes Benedict. (2009). First-year costs of treating prostate cancer: estimates from SEER-Medicare data. Prostate Cancer and Prostatic Diseases. 12(4). 355–360. 24 indexed citations

15.

Stokes, Michael E., Catherine E. Muehlenbein, Martin Marciniak, et al.. (2009). Neutropenia-Related Costs in Patients Treated with First-Line Chemotherapy for Advanced Non-Small Cell Lung Cancer. Journal of Managed Care Pharmacy. 15(8). 669–682. 47 indexed citations

16.

McGarry, Lisa J., Michael E. Stokes, & David R. Thompson. (2006). Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients. Thrombosis Journal. 4(1). 17–17. 36 indexed citations

17.

McCann, John J. & Michael E. Stokes. (1998). Color Spaces and Image Quality.. PICS. 140–144. 3 indexed citations

18.

Stokes, Michael E.. (1998). The Impact of Color Management Terminology on Image Quality.. PICS. 216–220.

19.

Stokes, Michael E., et al.. (1995). Limitations in Communicating Color Appearance with the ICC Profile Format. Color and Imaging Conference. 3(1). 155–159. 1 indexed citations

20.

Stokes, Michael E.. (1994). Quality Circles or Company Unions? A Look at Employee Involvement After Electromation and DuPont. The Knowledge Bank (The Ohio State University).

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact